报价延迟最少15分钟:2025/07/12 09:31 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
11.11 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.56/2.35
|
|
企业价值
954.46M
|
| 资产负债 |
|
每股账面净值
1.17
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/12 09:31 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066. |
